MEKTOVI

This brand name is authorized in Nigeria. It is also authorized in Australia, Austria, Croatia, Estonia, Finland, France, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, Poland, Romania, Spain, UK, United States.

Active ingredients

The drug MEKTOVI contains one active pharmaceutical ingredient (API):

1	Binimetinib UNII 181R97MR71 - BINIMETINIB
	Binimetinib is an ATP-uncompetitive, reversible inhibitor of the kinase activity of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway, which promotes cellular proliferation. Binimetinib inhibits activation of MEK by BRAF and inhibits MEK kinase activity.
	Read more about Binimetinib

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A4-100332	Tablet	Mektovi 15 mg Tablets TAB 15 mg 7 x 12's (in PVC/PVDC/Alu blisters)	Film-coated tablet (tablet). Yellow to dark yellow, unscored biconvex, ovaloid film-coated tablets approximately 12 mm in length and 5 mm in width, with the “A” logo debossed on one side of the tablet and “15” on the other side	26/01/2023

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
MEKTOVI Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EE03		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EE Mitogen-activated protein kinase (MEK) inhibitors
Discover more medicines within L01EE03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11948W, 11961M
EE	Ravimiamet	1780286, 1804407, 1872019
ES	Centro de información online de medicamentos de la AEMPS	1181315001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	175004
FR	Base de données publique des médicaments	67712453
GB	Medicines & Healthcare Products Regulatory Agency	362853, 392452
IE	Health Products Regulatory Authority	88989
IL	מִשְׂרַד הַבְּרִיאוּת	8865
IT	Agenzia del Farmaco	047197013, 047197025
JP	医薬品医療機器総合機構	4291058F1024
LT	Valstybinė vaistų kontrolės tarnyba	1086239, 1087044
NG	Registered Drug Product Database	A4-100332
NL	Z-Index G-Standaard, PRK	167223
PL	Rejestru Produktów Leczniczych	100411243
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68714001
US	FDA, National Drug Code	70255-010